CA3226176A1 - Il1ra derived peptides for treatment of diabetic nephropathy - Google Patents

Il1ra derived peptides for treatment of diabetic nephropathy Download PDF

Info

Publication number
CA3226176A1
CA3226176A1 CA3226176A CA3226176A CA3226176A1 CA 3226176 A1 CA3226176 A1 CA 3226176A1 CA 3226176 A CA3226176 A CA 3226176A CA 3226176 A CA3226176 A CA 3226176A CA 3226176 A1 CA3226176 A1 CA 3226176A1
Authority
CA
Canada
Prior art keywords
compound
amino acid
seq
use according
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3226176A
Other languages
English (en)
French (fr)
Inventor
Eva Steiness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serodus ApS
Original Assignee
Serodus ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus ApS filed Critical Serodus ApS
Publication of CA3226176A1 publication Critical patent/CA3226176A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3226176A 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy Pending CA3226176A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/069450 WO2023284947A1 (en) 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy

Publications (1)

Publication Number Publication Date
CA3226176A1 true CA3226176A1 (en) 2023-01-19

Family

ID=76958978

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3226176A Pending CA3226176A1 (en) 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy

Country Status (8)

Country Link
US (1) US20240216464A1 (https=)
EP (1) EP4351617B1 (https=)
JP (1) JP7839260B2 (https=)
CN (1) CN117642174A (https=)
AU (1) AU2021455992A1 (https=)
CA (1) CA3226176A1 (https=)
ES (1) ES3026437T3 (https=)
WO (1) WO2023284947A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
KR101317045B1 (ko) * 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
ES2600616T3 (es) * 2011-03-14 2017-02-10 Phlogo Aps Antagonistas del receptor de la interleucina-1
WO2017063657A1 (en) * 2015-10-14 2017-04-20 Phlogo Aps Il1ra-derived peptide antagonist
WO2018022982A1 (en) * 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Also Published As

Publication number Publication date
AU2021455992A1 (en) 2024-01-18
JP7839260B2 (ja) 2026-04-01
EP4351617B1 (en) 2025-03-26
WO2023284947A1 (en) 2023-01-19
EP4351617C0 (en) 2025-03-26
JP2024525669A (ja) 2024-07-12
EP4351617A1 (en) 2024-04-17
ES3026437T3 (en) 2025-06-11
US20240216464A1 (en) 2024-07-04
CN117642174A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
Takashima et al. Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
CN109475592B (zh) 用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物
CN1960758B (zh) 关节炎的治疗剂或预防剂
JP6728352B2 (ja) 胆汁酸に関係した障害の治療方法
Bernotiene et al. Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient mice
TW200817431A (en) Diuretic and natriuretic polypeptides
US20200188471A1 (en) Application of selective tnfr1 antagonist peptide sn10 in preparation of drugs for preventing and treating rheumatoid arthritis
US8058014B2 (en) Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
Zhang et al. Reversing CXCL10 deficiency ameliorates kidney disease in diabetic mice
Tacconi et al. Antibody-mediated delivery of VEGFC ameliorates experimental chronic colitis
Hu et al. Fibroblast growth factor 2 Is produced by renal tubular cells to act as a paracrine factor in maladaptive kidney repair after cisplatin nephrotoxicity
EP4351617B1 (en) Il1ra derived peptides for treatment of diabetic nephropathy
Toffoli et al. TRAIL treatment prevents renal morphological changes and TGF-β-induced mesenchymal transition associated with diabetic nephropathy
CA3244198C (en) Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy
JP2021529793A (ja) リウマチ関節炎治療用ペプチド及びその用途
EP4422659B1 (en) Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy
CN113748123B (zh) 用于治疗肺部炎症的组合物
WO2024011946A1 (en) Polypeptide dimers for the treatment of systemic sclerosis
WO2014188373A1 (en) Chromogranin-a-derived polypeptides and methods of use
WO2017063657A1 (en) Il1ra-derived peptide antagonist
HK40005282A (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
Bonnet Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases 2
JP2011093804A (ja) 関節リウマチ治療剤
HK1138333A (en) Methods of diagnosing and treating an inflammatory response

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250623

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250625

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250903

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250903

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250903

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250903

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250903